Companies / Thryv Therapeutics
Thryv Therapeutics
United States
Thryv Therapeutics is a clinical-stage biotechnology company advancing a portfolio of potent, selective inhibitors of serum and glucocorticoid-regulated kinase 1 (SGK1) as precision medicines for inherited channelopathies, cardiometabolic diseases and cardiomyopathies.
Thryv Therapeutics, based in United States, has 1 investor on file, among them Amzak Health.
Investors
1 investor on file| Investor | Evidence | Type |
|---|---|---|
| Portfolio page | Venture capital |
In the news
1 headline naming Thryv TherapeuticsEach headline is matched with evidence and opens on its outlet. Some come through the GDELT Project.
More from Amzak Health
16 companies on its checked portfolioIts portfolio leans to Healthcare & Biotech (100%).
A company is shown only after its own site answers and carries its name. Sites are checked again on a schedule, because domains lapse and get bought. Round stages and dates come from Fundup AI; investor links come from portfolio pages and rounds; other facts name their source when you point at them. How we grade the data
Get Thryv Therapeutics and its investors as data
Look up any company's investors, or any investor's full portfolio, through one API key or MCP. A free account also opens Ask AI searches and alerts when Amzak Health adds a company.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/companies/lqttrx.com/investors
# also
GET /v1/companies/lqttrx.com
GET /v1/companies/lqttrx.com/news